SELLAS Life Sciences (SLS) Total Current Liabilities (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Total Current Liabilities data on file, last reported at $6.5 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 6.27% year-over-year to $6.5 million in Q1 2026; TTM through Mar 2026 was $6.5 million, a 6.27% decrease from a year earlier, with the FY2025 full-year figure at $7.0 million, down 26.21% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $6.5 million, down from $7.0 million in the prior quarter.
• Over the last five years, Total Current Liabilities for SLS reached as high as $15.5 million in Q4 2022 and fell as low as $5.9 million in Q3 2025.
• Historically, Total Current Liabilities has averaged $10.8 million across 5 years, with a median of $11.7 million in 2023.
• Across the five-year window, Total Current Liabilities jumped 211.42% in 2022 and slumped 52.29% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $15.5 million in 2022, then slipped by 11.47% to $13.7 million in 2023, then plunged by 30.76% to $9.5 million in 2024, then decreased by 26.21% to $7.0 million in 2025, then dropped by 7.99% to $6.5 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $6.5 million in Q1 2026, $7.0 million in Q4 2025, and $5.9 million in Q3 2025.